Now live: Pro — the full 13F research suite for serious investorsSee pricing →
ACUTA CAPITAL PARTNERS, LLC

Q1 2024 · 13F-HR

ACUTA CAPITAL PARTNERS, LLCholdings as filed

Filed 2024-05-15 · accession 0001104659-24-061603

$153.9M
Reported value
33
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
67576A100OCULOCULAR THERAPEUTIX INC$24.0M15.6%2,635,287CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$9.9M6.43%162,302CommonSOLE
59045L106MERSANA THERAPEUTICS INC$9.7M6.30%2,164,628CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$9.6M6.21%3,333,333CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$8.8M5.72%326,787CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$8.3M5.40%64,162CommonSOLE
92243G108PCVXVAXCYTE INC$7.2M4.65%104,830CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$7.0M4.53%396,099CommonSOLE
89157D105TRMLTOURMALINE BIO INC$6.0M3.88%261,108CommonSOLE
03828A101APLTAPPLIED THERAPEUTICS INC$5.4M3.50%792,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$5.2M3.40%184,500CommonSOLE
254604101IRONDISC MEDICINE INC$4.8M3.11%76,800CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$4.6M3.01%143,777CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC$4.6M2.97%109,000CommonSOLE
00032Q104WHWKAADI BIOSCIENCES INC$4.3M2.81%1,849,402CommonSOLE
43157M102HILLEVAX INC$4.2M2.71%250,609CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS$3.7M2.38%78,403CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$3.5M2.27%199,433CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$3.1M1.98%465,079CommonSOLE
45258J102IMVTIMMUNOVANT INC$3.0M1.94%92,346CommonSOLE
92337C203VSTMVERASTEM INC$2.4M1.59%207,095CommonSOLE
03940C100ACLXGBXARCELLX INC$2.4M1.56%34,500CommonSOLE
50127T109KURAKURA ONCOLOGY INC.$1.9M1.25%90,000CommonSOLE
457669307INSMINSMED INC$1.7M1.09%61,718CommonSOLE
00847X104AGIOAGIOS PHARMA$1.6M1.05%55,262CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$1.4M0.93%103,992CommonSOLE
589492107MREOMEREO BIOPHARMA GROUP PLC$1.3M0.85%397,884CommonSOLE
55234L105LYRAGBPLYRA THERAPEUTICS INC$1.1M0.70%173,320CommonSOLE
52187K200CYPHLEAP THERAPEUTICS INC$942,0820.61%354,166CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL INC$933,8000.61%20,000CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC.$920,3600.60%13,300CommonSOLE
15117F807CLRBUSDCELLECTAR BIOSCIENCES INC.$571,1300.37%143,500CommonSOLE
67080N119NUVB/WSNUVATION BIO$27,4770.02%90,832CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.